Related Experiment Videos
Cardiac effects of combination therapy
1Department of Internal Medicine, Ochsner Clinic and Alton Ochsner Medical Foundation, New Orleans, Louisiana 70121, USA.
American Journal of Hypertension
|July 1, 1997
Summary
Combination therapy for hypertension, particularly with ACE inhibitors and calcium antagonists, shows promise for reducing left ventricular hypertrophy. However, combinations should primarily target blood pressure reduction.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension management often requires multiple drugs, yet research predominantly focuses on monotherapy.
- Current understanding of combination therapy for hypertension largely relies on extrapolations from monotherapy studies.
Purpose of the Study:
- To evaluate the efficacy of drug combinations in managing hypertension and associated conditions.
- To identify optimal drug classes for combination therapy, particularly for reducing left ventricular hypertrophy (LVH).
Main Methods:
- Review and synthesis of existing literature on antihypertensive drug combinations.
- Analysis of the potential benefits and drawbacks of specific drug classes in combination therapy.
Main Results:
- Angiotensin converting enzyme (ACE) inhibitors combined with calcium antagonists are suggested to be effective in reducing LVH.
- Drug classes stimulating the renin-angiotensin or sympathetic nervous systems may be less effective for LVH reduction.
- Specific recommendations for amlodipine in heart failure and verapamil in post-myocardial ischemia are discussed.
Conclusions:
- Combination therapy for hypertension should prioritize arterial pressure reduction.
- Secondary benefits, such as improving pathophysiologic conditions like LVH, should be considered cautiously.
- The efficacy of combined drugs does not automatically equate to enhanced benefits over monotherapy.